Tags

Type your tag names separated by a space and hit enter

Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
Mov Disord. 2018 02; 33(2):282-288.MD

Abstract

OBJECTIVE

Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms.

BACKGROUND

CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear.

METHODS

BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined.

RESULTS

CSF alpha-synuclein was lower in PD versus controls (P = .01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P < .01), and correlated weakly with MoCA recall scores (r = 0.23, P = .02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P < .01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42 , total-tau, and phosphorylated-tau (r = 0.41, 0.81, 0.43, respectively; Ps < .001).

CONCLUSION

Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Authors+Show Affiliations

Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA.Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA.Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.BioLegend Inc, Dedham, USA.Parkinson Disease and Movement Disorder Program, Department of Neurology, University of Chicago, Chicago, Illinois, USA.Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.Department of Neurology, Weill Cornell Medical College, New York, New York, USA.Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.No affiliation info availableDivision of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA.

Pub Type(s)

Journal Article
Multicenter Study
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29205509

Citation

Goldman, Jennifer G., et al. "Cerebrospinal Fluid, Plasma, and Saliva in the BioFIND Study: Relationships Among Biomarkers and Parkinson's Disease Features." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 33, no. 2, 2018, pp. 282-288.
Goldman JG, Andrews H, Amara A, et al. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord. 2018;33(2):282-288.
Goldman, J. G., Andrews, H., Amara, A., Naito, A., Alcalay, R. N., Shaw, L. M., Taylor, P., Xie, T., Tuite, P., Henchcliffe, C., Hogarth, P., Frank, S., Saint-Hilaire, M. H., Frasier, M., Arnedo, V., Reimer, A. N., Sutherland, M., Swanson-Fischer, C., Gwinn, K., & Kang, U. J. (2018). Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Movement Disorders : Official Journal of the Movement Disorder Society, 33(2), 282-288. https://doi.org/10.1002/mds.27232
Goldman JG, et al. Cerebrospinal Fluid, Plasma, and Saliva in the BioFIND Study: Relationships Among Biomarkers and Parkinson's Disease Features. Mov Disord. 2018;33(2):282-288. PubMed PMID: 29205509.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. AU - Goldman,Jennifer G, AU - Andrews,Howard, AU - Amara,Amy, AU - Naito,Anna, AU - Alcalay,Roy N, AU - Shaw,Leslie M, AU - Taylor,Peggy, AU - Xie,Tao, AU - Tuite,Paul, AU - Henchcliffe,Claire, AU - Hogarth,Penelope, AU - Frank,Samuel, AU - Saint-Hilaire,Marie-Helene, AU - Frasier,Mark, AU - Arnedo,Vanessa, AU - Reimer,Alyssa N, AU - Sutherland,Margaret, AU - Swanson-Fischer,Christine, AU - Gwinn,Katrina, AU - ,, AU - Kang,Un Jung, Y1 - 2017/12/04/ PY - 2017/06/26/received PY - 2017/10/08/revised PY - 2017/10/16/accepted PY - 2017/12/6/pubmed PY - 2019/5/17/medline PY - 2017/12/6/entrez KW - alpha-synuclein KW - amyloid KW - cerebrospinal fluid KW - postural instability gait difficulty KW - tau SP - 282 EP - 288 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 33 IS - 2 N2 - OBJECTIVE: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. BACKGROUND: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. METHODS: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. RESULTS: CSF alpha-synuclein was lower in PD versus controls (P = .01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P < .01), and correlated weakly with MoCA recall scores (r = 0.23, P = .02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P < .01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42 , total-tau, and phosphorylated-tau (r = 0.41, 0.81, 0.43, respectively; Ps < .001). CONCLUSION: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/29205509/Cerebrospinal_fluid_plasma_and_saliva_in_the_BioFIND_study:_Relationships_among_biomarkers_and_Parkinson's_disease_Features_ L2 - https://doi.org/10.1002/mds.27232 DB - PRIME DP - Unbound Medicine ER -